Scott T. Rottinghaus

Dr. Rottinghaus joined Enanta in August 2022. He brings more than 20 years of clinical experience in drug development, with expertise in a variety of therapeutic areas including rare disease, hematology, nephrology, neurology, dermatology, rheumatology, and infectious diseases. Prior to joining Enanta, Dr. Rottinghaus was Vice President and Head of Clinical Development for Hematology and Nephrology at Alexion, AstraZeneca Rare Disease, where he led development for several clinical assets, including ravulizumab, a complement C5 inhibitor for rare diseases. Before his time at Alexion, Dr. Rottinghaus was a senior director at Pfizer, driving the advancement of several drug programs such as tofacitinib in rheumatology and dermatology, as well as tigecycline, voriconazole, and anidulafungin in the infectious disease field. Earlier in his Pfizer career, he worked as a clinician on early-stage clinical trials for influenza vaccine development. Dr. Rottinghaus’ experience includes multiple NDA and MAA submissions and FDA Advisory Committee participation.